Update shared on05 Sep 2025
Fair value Increased 7.85%Consensus analyst price targets for Ingevity have risen to $65.25, reflecting increased confidence in continued earnings and free cash flow growth following a strong Q2 beat and improved operational outlook.
Analyst Commentary
- Q2 earnings beat, demonstrating stronger-than-expected financial performance.
- Shares rallied 21%, but further upside is anticipated.
- Company has reached an inflection point in both earnings growth and free cash flow generation.
- Improved outlook on sustained business momentum going forward.
- Confidence in continued operational execution and value creation.
What's in the News
- Ingevity affirmed full-year 2025 sales guidance at $1.25 billion to $1.40 billion.
- The company completed the repurchase of 2,052,153 shares (5.48%) for $146.62 million under its buyback program announced in 2022.
- No shares were repurchased between April 1 and June 30, 2025.
Valuation Changes
Summary of Valuation Changes for Ingevity
- The Consensus Analyst Price Target has risen from $60.50 to $65.25.
- The Consensus Revenue Growth forecasts for Ingevity has significantly fallen from 3.1% per annum to 1.8% per annum.
- The Future P/E for Ingevity has risen from 6.75x to 7.28x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.